Protective effects of berberine on radiation-induced lung injury via intercellular adhesion molecular-1 and transforming growth factor-beta-1 in patients with lung cancer
Protective effects of berberine on radiation-induced lung injury via intercellular adhesion molecular-1 and transforming growth factor-beta-1 in patients with lung cancer
复制标题
小檗碱通过细胞间粘附分子-1和转化生长因子-β-1对肺癌患者放射性肺损伤的保护作用
DOI：
10.1016/j.ejca.2008.07.040
复制
发表时间：
2008-11-01
影响因子：
8.4
通讯作者：
Zhao, Yuxia
中科院分区：
文献类型：
--
作者：
Liu, Yunfang;Yu, Huiming;Zhao, Yuxia
目的：探讨小檗碱对非小细胞肺癌（NSCLC）放疗患者放射性肺损伤（RILI）的保护作用。患者和方法：在这项随机双盲研究中，90例非小细胞肺癌患者被分为两组。试验组放疗加小檗碱治疗，对照组放疗加安慰剂治疗，疗程6周。测定可溶性细胞间粘附分子-1 （sICAM-1）和转化生长因子- β -1 （TGF-1）。分别于治疗后6周和6个月评估RILI和肺功能。结果：入选的90例患者中，对照组43例，试验组42例完成研究。在6周和6个月时，试验组的RILI发生率显著低于对照组（45.2%比72.1%，35.7%比65.1%，P均< 0.05）。试验组sICAM-1水平在第6周和第12周显著低于对照组（373.64 +/- 89.33 vs 459.53 +/- 123.59, 447.83 +/- 111.21 vs 513.91 +/- 150.46， P均< 0.01），血浆tgf - β 1水平在第3周和第6周显著低于对照组（5.43 +/- 1.47 vs 6.22 +/- 1.78, 5.93 +/- 2.39 vs 7.67 +/- 2.74， P分别< 0.05和0.01）。黄连素组与安慰剂组FEV1 （P = 0.033）和DLCO （P = 0.003）差异有统计学意义。独立样本t检验显示，试验组第6周FVC较基线下降（P < 0.05），第6个月FEV1和DLCO较基线下降（P分别< 0.05和0.01）均显著小于对照组。结论：小檗碱可显著降低RILI的发生率，改善PF，降低sICAM-1和tcf - β 1水平。确切的机制还有待进一步探索。(C) 2008 Elsevier Ltd版权所有。
Purpose: To investigate the protective effects of berberine on radiation-induced lung injury (RILI) in non-small cell lung cancer (NSCLC) patients treated with radiotherapy. Patients and methods: In this randomised, double-blind study, 90 patients with NSCLC were divided into two groups. The trial group received radiation therapy plus berberine, and the control group received radiation therapy plus a placebo for 6 weeks. Soluble intercellular adhesion molecular-1 (sICAM-1) and transforming growth factor-beta-1 (TGF-1) were measured. RILI and pulmonary function were evaluated at 6 weeks and 6 months after treatment, respectively.Results: Of the 90 patients enroled, 43 in the control group and 42 in the trial group completed the study. The incidence of RILI was significantly lower in the trial group at 6 weeks and 6 months than that in the control group (45.2% versus 72.1% and 35.7% versus 65.1%, respectively, both P < 0.05). sICAM-1 levels in the trial group were significantly lower at weeks 6 and 12 (373.64 +/- 89.33 versus 459.53 +/- 123.59 and 447.83 +/- 111.21 versus 513.91 +/- 150.46, both P < 0.01), and plasma TGF-beta 1 levels were lower at week 3 and 6 (5.43 +/- 1.47 versus 6.22 +/- 1.78 and 5.93 +/- 2.39 versus 7.67 +/- 2.74, P < 0.05 and 0.01, respectively) in comparison with the control group. Significant differences were observed in FEV1 (P = 0.033) and DLCO (P = 0.003) between patients receiving berberine and those receiving placebo. Independent-samples T-test showed reductions from baseline FVC at week 6 (P < 0.05), and FEV1 and DLCO at month 6 (P < 0.05 and 0.01, respectively) in the trial group were significantly smaller than that in the control group.Conclusion: Berberine significantly reduced the incidence of RILI, improved PF and decreased the levels of sICAM-1 and TCF-beta 1. The exact mechanisms remain to be further explored. (C) 2008 Elsevier Ltd. All rights reserved.